Pharmsintez sold the Estonian plant Kevelt. The buyer was Dmitry Genkin, Chairman of the Board of Directors of the company. Transactions amounted to €224.8 thousand. At the same time, the parties entered into an option, according to which Pharmsintez has the right to buy back the shares within ten years. Companies also offset the counterclaims on the debt of Kewelt to Pharmsintez, which now amounts to €1.54 mln. Remaining amount of Pharmsintez's debt to Kewelt is $22.3 th.